pMAL™
The system uses the pMAL™ vectors which are designed so that insertion of a target gene results in an MBP fusion protein. pMAL-c5 series has an exact deletion of the malE signal sequence, resulting in cytoplasmic expression of the fusion protein. pMAL-p5 series contains the normal malE signal sequence, which directs the fusion protein through the cytoplasmic membrane. pMAL-p5 fusion proteins capable of being exported can be purified from the periplasm. Between the malE sequence and the polylinker there is a spacer sequence coding for 10 asparagine residues. This spacer insulates MBP from the protein of interest, increasing the chances that a particular fusion will bind tightly to the amylose resin. The vectors also include a sequence coding for the recognition site of a specific protease. This allows the protein of interest to be cleaved from MBP after purification, without adding any vector-derived residues to the protein (1). For this purpose, the polylinker includes a restriction site superimposed on the sequence coding for the site of the specific protease, where the gene of interest is inserted. A number of other useful sites are present directly downstream to facilitate cloning.
(1) LaVallie, E. R. and McCoy, J. M. (1990). In F. M. Ausebel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith and K. Struhl (Eds.), Current Protocols in Molecular Biology (pp. 16.4.1–16.4.17). New York: John Wiley & Sons, Inc.
pMAL™ is a trademark of New England Biolabs, Inc.
Choose Type:
- Cleavage of the Fusion Protein Generated Using The pMAL Protein Fusion and Purification System (E8200)
- Cloning a PCR Fragment Into a pMAL Expression Vector (E8200)
- Isolation of MBP-fusion protein using Anti-MBP Magnetic Beads
- Isolation of MBP-fusion protein using Amylose Magnetic Beads
- Purification of a Fusion Protein generated by The pMAL Protein Fusion and Purification System (E8200)
- Separating the Protein of Interest from MBP after Protease Cleavage Using The pMAL Protein Fusion and Purification System (E8200)
- Western Transfer Protocol for Anti-MBP Monoclonal Antibody
- Western Transfer Protocol for Anti-MBP Monoclonal Antibody, HRP Conjugated
- Quick Start Guide (E8200)
- Protein Expression with T7 Express strains
- Expression Using SHuffle®
-
Avoid Common Obstacles in Protein Expression
Read how to avoid common obstacles in protein expression that prevent interactions with cellular machinery.
- Competent Cell Brochure
- Protein Expression & Purification Brochure
- Competent Cell Product Comparison
- Protein Expression and Purification Selection Chart
- Convenient Formats of Competent Cells
Feature Articles
Brochures
Selection Tools
Usage Guidelines
- Reliable E. coli expression – Substantial yields (up to 100 mg/L) in more than 75% of the cases tested
- Enhances solubility – Proteins that are insoluble when expressed in E. coli unfused are often soluble when fused to MBP (1).
- Expression in either the cytoplasm or periplasm – Periplasmic expression enhances folding of protein with disulfide bond.
References
- Kapust, R.B. and Waugh, D.S. (1999) Prot. Sci., 8, 1668–1674. PMID: 10452611
Lane 1: Protein Ladder (NEB #P7703).
Lane 2: uninduced cells.
Lane 3: induced cells.
Lane 4: purified protein eluted from amylose column with maltose.
Lane 5: purified protein after Factor Xa cleavage.
Lane 6: paramyosin fragment in flow-through from second amylose column.
This product is covered by one or more patents, trademarks and/or copyrights owned or controlled by New England Biolabs, Inc (NEB).
While NEB develops and validates its products for various applications, the use of this product may require the buyer to obtain additional third party intellectual property rights for certain applications.
For more information about commercial rights, please contact NEB's Global Business Development team at [email protected].
This product is intended for research purposes only. This product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
